{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T17:54:36Z","timestamp":1785779676462,"version":"3.56.0"},"reference-count":25,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>\n                    Gastric cancer is among the most common cancers and represents a major public health problem worldwide. New therapeutic strategies and drugs are needed. Anti-angiogenic agents targeting the Vascular Endothelial Growth Factor (VEGF) are used in combination therapy in the clinic, although their efficacy remains modest. We believe that these large anti-VEGF antibodies could be advantageously replaced by smaller peptides with better tissue penetration. In this study, we evaluate the efficacy of a previously described dimer peptide ligand of VEGF,\n                    <jats:bold>D6<\/jats:bold>\n                    , in inhibiting the proliferation of gastric cancer cells and the growth of the corresponding murine xenograft. The activity of the\n                    <jats:bold>D6<\/jats:bold>\n                    peptide in these assays was comparable to that of bevacizumab, the positive control antibody, although the peptide required repeated injections at higher molar concentrations. These promising results justify the continued optimization of the peptide dimer, currently under investigation in our laboratory.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0344142","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T17:21:25Z","timestamp":1785777685000},"page":"e0344142","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["A dimer peptide ligand of vascular endothelial growth factor slows the progression of human gastric tumors in mouse xenografts"],"prefix":"10.1371","volume":"21","author":[{"given":"Xiaoqing","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haofeng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3315-4797","authenticated-orcid":true,"given":"Jia","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6566-8170","authenticated-orcid":true,"given":"Elodie","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Gaucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3098-5317","authenticated-orcid":true,"given":"Sylvain","family":"Broussy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"issue":"10494","key":"pone.0344142.ref001","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/S0140-6736(25)00052-2","article-title":"Gastric cancer","volume":"405","author":"R Sundar","year":"2025","journal-title":"Lancet"},{"issue":"4","key":"pone.0344142.ref002","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/ajco.13174","article-title":"Anti-angiogenic therapies for gastric cancer","volume":"15","author":"S Hironaka","year":"2019","journal-title":"Asia Pac J Clin Oncol"},{"issue":"1","key":"pone.0344142.ref003","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10120-014-0397-4","article-title":"Vascular endothelial growth factor a inhibition in gastric cancer","volume":"18","author":"DJ Park","year":"2015","journal-title":"Gastric Cancer"},{"key":"pone.0344142.ref004","doi-asserted-by":"crossref","first-page":"1307860","DOI":"10.3389\/fphar.2023.1307860","article-title":"Recent advances of anti-angiogenic inhibitors targeting VEGF\/VEGFR axis","volume":"14","author":"L Wang","year":"2024","journal-title":"Front Pharmacol"},{"issue":"11","key":"pone.0344142.ref005","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"H Wilke","year":"2014","journal-title":"Lancet Oncol"},{"issue":"13","key":"pone.0344142.ref006","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","article-title":"Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction","volume":"34","author":"J Li","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"pone.0344142.ref007","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.24.00055","article-title":"INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer","volume":"43","author":"N Pavlakis","year":"2025","journal-title":"J Clin Oncol"},{"key":"pone.0344142.ref008","doi-asserted-by":"crossref","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in cancer treatment: A review of 15 years of clinical experience and future outlook","volume":"86","author":"J Garcia","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"pone.0344142.ref009","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12957-024-03624-x","article-title":"Efficacy and safety of neoadjuvant bevacizumab plus chemotherapy in locally advanced gastric cancer patients: a retrospective, comparative study","volume":"23","author":"B Yin","year":"2025","journal-title":"World J Surg Oncol"},{"key":"pone.0344142.ref010","first-page":"33","article-title":"Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy","volume":"13","author":"E Cruz","year":"2019","journal-title":"Biologics"},{"issue":"4","key":"pone.0344142.ref011","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1158\/0008-5472.CAN-13-2440","article-title":"An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors","volume":"74","author":"ECW Breij","year":"2014","journal-title":"Cancer Res"},{"issue":"8","key":"pone.0344142.ref012","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/00001813-200309000-00006","article-title":"Antitumor activity of the alkylating oligopeptides J1 (L-melphalanyl-p-L-fluorophenylalanine ethyl ester) and P2 (L-prolyl-m-L-sarcolysyl-p-L-fluorophenylalanine ethyl ester): comparison with melphalan","volume":"14","author":"J Gullbo","year":"2003","journal-title":"Anti-Cancer Drugs"},{"key":"pone.0344142.ref013"},{"key":"pone.0344142.ref014"},{"issue":"51","key":"pone.0344142.ref015","doi-asserted-by":"crossref","first-page":"17754","DOI":"10.1021\/bi981931e","article-title":"Novel peptides selected to bind vascular endothelial growth factor target the receptor-binding site","volume":"37","author":"WJ Fairbrother","year":"1998","journal-title":"Biochemistry"},{"issue":"33","key":"pone.0344142.ref016","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1021\/acs.biochem.5b00722","article-title":"Vascular Endothelial Growth Factor Peptide Ligands Explored by Competition Assay and Isothermal Titration Calorimetry","volume":"54","author":"M Reille-Seroussi","year":"2015","journal-title":"Biochemistry"},{"issue":"48","key":"pone.0344142.ref017","article-title":"Structural and ITC Characterization of Peptide-Protein Binding: Thermodynamic Consequences of Cyclization Constraints, a Case Study on Vascular Endothelial Growth Factor Ligands","volume":"28","author":"J-F Gaucher","year":"2022","journal-title":"Chemistry"},{"key":"pone.0344142.ref018","doi-asserted-by":"crossref","first-page":"9753","DOI":"10.1021\/acs.jmedchem.3c00561","article-title":"Dimer peptide ligands of vascular endothelial growth factor: optimizing linker length for high affinity and antiangiogenic activity","volume":"66","author":"X Ye","year":"2023","journal-title":"J Med Chem"},{"key":"pone.0344142.ref019","doi-asserted-by":"crossref","first-page":"734544","DOI":"10.3389\/fphar.2021.734544","article-title":"A Cyclic Peptide Epitope of an Under-Explored VEGF-B Loop 1 Demonstrated In Vivo Anti-Angiogenic and Anti-Tumor Activities","volume":"12","author":"L Wang","year":"2021","journal-title":"Front Pharmacol"},{"issue":"3","key":"pone.0344142.ref020","first-page":"614","article-title":"An SV40-immortalized human corneal epithelial cell line and its characterization","volume":"36","author":"K Araki-Sasaki","year":"1995","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"pone.0344142.ref021","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/nprot.2008.75","article-title":"Neutral red uptake assay for the estimation of cell viability\/cytotoxicity","volume":"3","author":"G Repetto","year":"2008","journal-title":"Nat Protoc"},{"key":"pone.0344142.ref022","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"LM Sherwood","year":"1971","journal-title":"N Engl J Med"},{"issue":"7","key":"pone.0344142.ref023","doi-asserted-by":"crossref","first-page":"11990","DOI":"10.18632\/oncotarget.14467","article-title":"Autocrine VEGF signaling promotes cell proliferation through a PLC-dependent pathway and modulates Apatinib treatment efficacy in gastric cancer","volume":"8","author":"Y Lin","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"pone.0344142.ref024","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41392-022-00904-4","article-title":"Therapeutic peptides: current applications and future directions","volume":"7","author":"L Wang","year":"2022","journal-title":"Sig Transduct Target Ther"},{"issue":"1","key":"pone.0344142.ref025","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41392-024-02107-5","article-title":"Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines","volume":"10","author":"W Xiao","year":"2025","journal-title":"Sig Transduct Target Ther"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0344142","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T17:21:29Z","timestamp":1785777689000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0344142"}},"subtitle":[],"editor":[{"given":"Alireza","family":"Shoari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":25,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0344142","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]}}}